Immune checkpoint blockade in HIV

Impact of anti-PD-1 and anti-CTLA-4 on the HIV reservoir in people living with HIV with cancer on antiretroviral therapy: The AIDS Malignancy Consortium-095 study

(2021) Thomas A Rasmussen et al.   CLINICAL INFECTIOUS DISEASES

Response Rates to Anti–PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase

(2021) Cristina Valero et al.   JAMA Oncology

Suspected Immune-Related Adverse Events with an Anti-PD-1 Inhibitor in Healthy People with HIV

(2021) Cynthia L. GAY et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Next generation of immune checkpoint inhibitors and beyond

(2021) Julian A. Marin-Acevedo et al.   Journal of Hematology & Oncology

The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor Tim-3 in infected CD4+ T cells

(2021) Rajesh Abraham Jacob et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Neutrophils promote T-cell activation through the regulated release of CD44-bound Galectin-9 from the cell surface during HIV infection

(2021) Garett Dunsmore et al.   PLOS BIOLOGY

TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells

(2020) Elena Vendrame et al.   AIDS

Combination Immune Checkpoint Blockade to Reverse HIV Latency

(2020) Renée M. Van der Sluis et al.   JOURNAL OF IMMUNOLOGY

HIV-1 Vpu downregulates Tim-3 from the surface of infected CD4+ T cells

(2020) Jérémie Prévost et al.   JOURNAL OF VIROLOGY

The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies

(2020) Lillian B. Cohn et al.   Cell Host & Microbe

Galectin-9 and VISTA Expression Define Terminally Exhausted T Cells in HIV-1 Infection

(2020) Shima Shahbaz et al.   JOURNAL OF IMMUNOLOGY

CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption

(2020) Justin Harper et al.   NATURE MEDICINE

TIGIT Blockade: A Multipronged Approach to Target the HIV Reservoir

(2020) Kayla A. Holder et al.   Frontiers in Cellular and Infection Microbiology

Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection

(2020) Maria Gonzalez-Cao et al.   JAMA Oncology

Selective Upregulation of CTLA-4 on CD8+ T Cells Restricted by HLA-B*35Px Renders them to an Exhausted Phenotype in HIV-1 infection

(2020) Shokrollah Elahi et al.   PLoS Pathogens

CTLA-4 Blockade, during HIV Virus-Like Particles Immunization, Alters HIV-Specific B-Cell Responses

(2020) Phoebe E. Lewis et al.   Vaccines

CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ T Cells

(2020) Matthias Braun et al.   IMMUNITY

Effect of the use of Galectin-9 and blockade of TIM-3 receptor in the latent cellular reservoir of HIV-1

(2020) Marta Sanz et al.   JOURNAL OF VIROLOGY

TCF-1 regulates HIV-specific CD8+ T cell expansion capacity

(2020) Rachel L. Rutishauser et al.   JCI Insight

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells

(2019) Sema Kurtulus et al.   IMMUNITY

Intratumoral Tcf1+PD-1+CD8+ T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy

(2019) Imran Siddiqui et al.   IMMUNITY

Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer

(2019) Michael R. Cook et al.   JAMA Oncology

PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals

(2019) Rémi Fromentin et al.   Nature Communications

Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART

(2019) John K. Bui et al.   PLoS One

Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

(2019) Brian C. Miller et al.   NATURE IMMUNOLOGY

Rational design of anti-GITR-based combination immunotherapy

(2019) Roberta Zappasodi et al.   NATURE MEDICINE

Anti-PD-1 Blockade with Nivolumab with and without Therapeutic Vaccination for Virally Suppressed Chronic Hepatitis B: A Pilot Study

(2019) Edward Gane et al.   JOURNAL OF HEPATOLOGY

Assessment of the Safety of Pembrolizumab in Patients With HIV and Advanced Cancer—A Phase 1 Study

(2019) Thomas S. Uldrick et al.   JAMA Oncology

PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic SIV-infected macaques on antiretroviral therapy

(2019) Elena Bekerman et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2019) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cells with high PD-1 expression are associated with lower HIV-specific immune responses despite long-term antiretroviral therapy

(2019) Bernard J.C. Macatangay et al.   AIDS

Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency

(2018) Vanessa A. Evans et al.   AIDS

Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection

(2018) E P Scully et al.   ANNALS OF ONCOLOGY

Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies

(2018) Frederick Arce Vargas et al.   CANCER CELL

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

(2018) Elizabeth Colston et al.   PLoS One

Anti–CTLA-4 therapy requires an Fc domain for efficacy

(2018) Jessica R. Ingram et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Regulatory T Cells As Potential Targets for HIV Cure Research

(2018) Adam J. Kleinman et al.   Frontiers in Immunology

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

(2018) Hanjie Li et al.   CELL

Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

(2018) Moshe Sade-Feldman et al.   CELL

Immune Protection of SIV Challenge by PD-1 Blockade During Vaccination in Rhesus Monkeys

(2018) Enxiang Pan et al.   Frontiers in Immunology

CTLA-4 + PD-1 − Memory CD4 + T Cells Critically Contribute to Viral Persistence in Antiretroviral Therapy-Suppressed, SIV-Infected Rhesus Macaques

(2017) Colleen S. McGary et al.   IMMUNITY

Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy

(2017) Cynthia L. Gay et al.   JOURNAL OF INFECTIOUS DISEASES

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

(2017) Alexander C. Huang et al.   NATURE

Perturbed CD8+ T cell TIGIT/CD226/PVR axis despite early initiation of antiretroviral treatment in HIV infected individuals

(2017) Johanna Tauriainen et al.   Scientific Reports

T Cell Factor 1-Expressing Memory-like CD8 + T Cells Sustain the Immune Response to Chronic Viral Infections

(2016) Daniel T. Utzschneider et al.   IMMUNITY

Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease

(2016) John Attanasio et al.   IMMUNITY

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

(2016) Se Jin Im et al.   NATURE

CXCR5+ follicular cytotoxic T cells control viral infection in B cell follicles

(2016) Yew Ann Leong et al.   NATURE IMMUNOLOGY

PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals

(2016) Riddhima Banga et al.   NATURE MEDICINE

Monoclonal regulatory T cells provide insights into T cell suppression

(2016) Céline Gubser et al.   Scientific Reports

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

(2016) Glen M. Chew et al.   PLoS Pathogens

CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART

(2016) Rémi Fromentin et al.   PLoS Pathogens

Exhaustion of Activated CD8 T Cells Predicts Disease Progression in Primary HIV-1 Infection

(2016) Matthias Hoffmann et al.   PLoS Pathogens

Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma

(2015) Fiona Wightman et al.   AIDS

Nef promotes evasion of human immunodeficiency virus type 1-infected cells from the CTLA-4-mediated inhibition of T-cell activation

(2015) Mohamed El-Far et al.   JOURNAL OF GENERAL VIROLOGY

The Upregulation of LAG-3 on T Cells Defines a Subpopulation with Functional Exhaustion and Correlates with Disease Progression in HIV-Infected Subjects

(2015) Xiaoling Tian et al.   JOURNAL OF IMMUNOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

(2015) D. S. Thommen et al.   Cancer Immunology Research

Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease

(2014) Leslie R. Cockerham et al.   AIDS

Galectin-9 Is Rapidly Released During Acute HIV-1 Infection and Remains Sustained at High Levels Despite Viral Suppression Even in Elite Controllers

(2014) Ravi Tandon et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Immune Activation Driven by CTLA-4 Blockade Augments Viral Replication at Mucosal Sites in Simian Immunodeficiency Virus Infection

(2014) V. Cecchinato et al.   JOURNAL OF IMMUNOLOGY

Regulatory T Cells Inhibit Dendritic Cells by Lymphocyte Activation Gene-3 Engagement of MHC Class II

(2014) Bitao Liang et al.   JOURNAL OF IMMUNOLOGY

Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo

(2014) Rituparna Das et al.   JOURNAL OF IMMUNOLOGY

CEACAM1 regulates TIM-3-mediated tolerance and exhaustion

(2014) Yu-Hwa Huang et al.   NATURE

The human immunodeficiency virus type 1 Vpr protein upregulates PVR via activation of the ATR-mediated DNA damage response pathway

(2013) L. Vassena et al.   JOURNAL OF GENERAL VIROLOGY

Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells

(2012) S Liu et al.   CELL DEATH AND DIFFERENTIATION

Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1

(2012) Shigeki Chiba et al.   NATURE IMMUNOLOGY

Vstm3 is a member of the CD28 family and an important modulator of T-cell function

(2011) Steven D. Levin et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions

(2011) N. Joller et al.   JOURNAL OF IMMUNOLOGY

Protective HIV-specific CD8+ T cells evade Treg cell suppression

(2011) Shokrollah Elahi et al.   NATURE MEDICINE

Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation

(2011) Kajsa Wing et al.   TRENDS IN IMMUNOLOGY

Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1

(2010) Xinyuan Zhou et al.   IMMUNITY

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

(2008) R. Brad Jones et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Human Immunodeficiency Virus Type 1 Nef Induces Programmed Death 1 Expression through a p38 Mitogen-Activated Protein Kinase-Dependent Mechanism

(2008) K. Muthumani et al.   JOURNAL OF VIROLOGY